Supporting the mental health and wellbeing of over 4 million people in Australia living with cardiovascular disease (CVD) is crucial to them avoiding further heart attacks or strokes.
Graphite founder takes drug to recently-launched Kamau Therapeutics for a second chance: #ASH23
SAN DIEGO — After Graphite Bio’s implosion, Matthew Porteus wants to do things differently. The Stanford researcher’s stint at the biotech ended with Graphite selling